Literature DB >> 28551355

Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance.

Max C Petersen1, Gerald I Shulman2.   

Abstract

Although ample evidence links hepatic lipid accumulation with hepatic insulin resistance, the mechanistic basis of this association is incompletely understood and controversial. Diacylglycerols (DAGs) and ceramides have emerged as the two best-studied putative mediators of lipid-induced hepatic insulin resistance. Both lipids were first associated with insulin resistance in skeletal muscle and were subsequently hypothesized to mediate insulin resistance in the liver. However, the putative roles for DAGs and ceramides in hepatic insulin resistance have proved more complex than originally imagined, with various genetic and pharmacologic manipulations yielding a vast and occasionally contradictory trove of data to sort. In this review we examine the state of this field, turning a critical eye toward both DAGs and ceramides as putative mediators of lipid-induced hepatic insulin resistance.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ceramide; ectopic lipid; insulin receptor kinase; insulin resistance; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; protein kinase C epsilon

Mesh:

Substances:

Year:  2017        PMID: 28551355      PMCID: PMC5499157          DOI: 10.1016/j.tips.2017.04.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  124 in total

1.  Mechanism of insulin resistance in A-ZIP/F-1 fatless mice.

Authors:  J K Kim; O Gavrilova; Y Chen; M L Reitman; G I Shulman
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

2.  Prevention of fat-induced insulin resistance by salicylate.

Authors:  J K Kim; Y J Kim; J J Fillmore; Y Chen; I Moore; J Lee; M Yuan; Z W Li; M Karin; P Perret; S E Shoelson; G I Shulman
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate.

Authors:  C Schmitz-Peiffer; D L Craig; T J Biden
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

4.  Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473.

Authors:  K M Schubert; M P Scheid; V Duronio
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

5.  Association of nonalcoholic fatty liver disease with insulin resistance.

Authors:  G Marchesini; M Brizi; A M Morselli-Labate; G Bianchi; E Bugianesi; A J McCullough; G Forlani; N Melchionda
Journal:  Am J Med       Date:  1999-11       Impact factor: 4.965

6.  Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells.

Authors:  M Salinas; R López-Valdaliso; D Martín; A Alvarez; A Cuadrado
Journal:  Mol Cell Neurosci       Date:  2000-02       Impact factor: 4.314

7.  Mechanism by which metformin reduces glucose production in type 2 diabetes.

Authors:  R S Hundal; M Krssak; S Dufour; D Laurent; V Lebon; V Chandramouli; S E Inzucchi; W C Schumann; K F Petersen; B R Landau; G I Shulman
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

8.  Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus.

Authors:  G Boden; X Chen; T P Stein
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-01       Impact factor: 4.310

9.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Authors:  Kitt Falk Petersen; Elif Arioglu Oral; Sylvie Dufour; Douglas Befroy; Charlotte Ariyan; Chunli Yu; Gary W Cline; Alex M DePaoli; Simeon I Taylor; Phillip Gorden; Gerald I Shulman
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

10.  Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes.

Authors:  Mirja Tiikkainen; Marjo Tamminen; Anna-Maija Häkkinen; Robert Bergholm; Satu Vehkavaara; Juha Halavaara; Kari Teramo; Aila Rissanen; Hannele Yki-Järvinen
Journal:  Obes Res       Date:  2002-09
View more
  87 in total

1.  Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.

Authors:  Leigh Goedeke; Rachel J Perry; Gerald I Shulman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

2.  FoxO1 Is Required for Most of the Metabolic and Hormonal Perturbations Produced by Hepatic Insulin Receptor Deletion in Male Mice.

Authors:  Alisha V Ling; Mary E Gearing; Ivana Semova; Dong-Ju Shin; Rebecca Clements; Zon W Lai; Sudha B Biddinger
Journal:  Endocrinology       Date:  2018-03-01       Impact factor: 4.736

Review 3.  Mechanisms of Insulin Action and Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

4.  Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain.

Authors:  Gregory N Ruegsegger; Patrick M Vanderboom; Surendra Dasari; Katherine A Klaus; Parijat Kabiraj; Christina B McCarthy; Claudia F Lucchinetti; K Sreekumaran Nair
Journal:  JCI Insight       Date:  2019-09-19

5.  A Membrane-Bound Diacylglycerol Species Induces PKCϵ-Mediated Hepatic Insulin Resistance.

Authors:  Kun Lyu; Ye Zhang; Dongyan Zhang; Mario Kahn; Kasper W Ter Horst; Marcos R S Rodrigues; Rafael C Gaspar; Sandro M Hirabara; Panu K Luukkonen; Seohyuk Lee; Sanjay Bhanot; Jesse Rinehart; Niels Blume; Morten Grønbech Rasch; Mireille J Serlie; Jonathan S Bogan; Gary W Cline; Varman T Samuel; Gerald I Shulman
Journal:  Cell Metab       Date:  2020-09-02       Impact factor: 27.287

Review 6.  Role of mitochondria in pathogenesis of type 2 diabetes mellitus.

Authors:  Pankaj Prasun
Journal:  J Diabetes Metab Disord       Date:  2020-11-02

7.  Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates.

Authors:  Leigh Goedeke; Liang Peng; Valle Montalvo-Romeral; Gina M Butrico; Sylvie Dufour; Xian-Man Zhang; Rachel J Perry; Gary W Cline; Paul Kievit; Keefe Chng; Kitt Falk Petersen; Gerald I Shulman
Journal:  Sci Transl Med       Date:  2019-10-02       Impact factor: 17.956

8.  Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study.

Authors:  Ian J Neeland; Shruti Singh; Darren K McGuire; Gloria L Vega; Thomas Roddy; Dermot F Reilly; Jose Castro-Perez; Julia Kozlitina; Philipp E Scherer
Journal:  Diabetologia       Date:  2018-08-29       Impact factor: 10.122

Review 9.  Muscle and adipose tissue insulin resistance: malady without mechanism?

Authors:  Daniel J Fazakerley; James R Krycer; Alison L Kearney; Samantha L Hocking; David E James
Journal:  J Lipid Res       Date:  2018-07-27       Impact factor: 5.922

Review 10.  Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity.

Authors:  W Timothy Garvey; Jeffrey I Mechanick
Journal:  Obesity (Silver Spring)       Date:  2020-03       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.